Hepion pharmaceuticals announces positive top line data for low dose crv431 in phase 2a 'ambition' clinical trial for treatment of advanced nash

Crv431 demonstrated to be generally safe and well tolerated clinically significant reductions in important biomarkers, alt and ast, observed in 28 days study continuing with higher dose edison, nj / accesswire / december 29 , 2020 / hepion pharmaceuticals, inc. (nasdaq:hepa)("hepion"), a clinical stage biopharmaceutical company focused on artificial intelligence ("ai")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("nash") and liver disease, today announced top line data from the low dose cohort in the company's phase 2a ‘ambition' clinical trial of crv431, an oral, once daily novel cyclophilin inhibitor. this phase 2a study is continuing with the higher dose of 225 mg crv431, with nash patient dosing expected to be completed in q1-2021.
HEPA Ratings Summary
HEPA Quant Ranking